Personalized tacrolimus dosing for children after transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 1 and 18 years old.
- Child is receiving a first-time kidney, liver, or heart transplant.
- Child will be taking tacrolimus (immediate-release) as main immunosuppressant.
- Child has not had a previous liver transplant or any lung or intestinal transplant.
- Parent or guardian agrees to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Hear when a new Solid Organ Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.